IXJ holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 71.66% at a quoted market price (level 1), 16 issuer countries.

IXJ's largest investment is ELI Lilly Co at 10.93% of net assets. Johnson Johnson and Abbvie Inc follow; the three together are 23.1%. Ten companies are 47.87% of the fund; the other 113 share the rest. Among the 721 equity funds measured here, IXJ behaves like 29.5 holdings against a median of 42.4 — close to the median. Across 28 quarterly filings IXJ has become more concentrated: it behaved like 42.6 at 2019-09-30 and 29.5 at 2026-06-30. Between the 2026-03-31 and 2026-06-30 filings 4 positions were added and 5 dropped; 6.6% of the weight moved. the United States is the largest country at 70.01% of the portfolio, across 16 countries in the filing.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-09-30 and 2026-06-30, IXJ went from behaving like 42.6 equally weighted positions to 29.5 — 31% fewer, while its top ten went from 38.53% to 47.87% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

IXJ's filing lists 124 positions including 1.06% of net assets in securities-lending cash collateral. Counted as filed the fund reads 29.5 effective holdings with a top ten of 47.79%; on its own investments — the figure above — it reads 29.5 with a top ten of 47.87%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.

The 15 largest of 123 positions in IXJ's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: IXJ.csv.gz.

Share of IXJ's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of IXJ's own filings, 84 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.09 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IXJ.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $40m was out to 8 borrowers, 1.04% of net assets. The largest, UBS AG, held 30.6% of it.

Cash collateral reported against the loan: 1.06% of net assets, 101.7% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IXJ has filed, with each borrower: IXJ.json · all funds.

124 positions became 123: 4 added (0.4% of the fund at the later date), 5 dropped (0.4% at the earlier date). Half the sum of all weight changes, a turnover proxy: 6.6%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IXJ compared this way, as a feed: changes.xml · all funds: filings received.

New: VEEVA SYSTEMS INC. (0.35%), XAV HEALTH CARE SEP26 (0.02%), SWISS FRANC (0.01%), HOLOGIC INC CVR (0.00%). Gone: HOLOGIC, INC. (0.22%), Pro Medicus Ltd (0.06%), M3, Inc. (0.06%), SYSMEX CORPORATION (0.06%), Zealand Pharma A/S (0.04%).

71.7% of IXJ is carried at a quoted market price (fair-value level 1). Categories and levels are the filer's, from Form N-PORT; what a low level-1 share does and does not mean is in the measure's page.

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $3.84B. Notional of an interest-rate or currency swap is not equity exposure.

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IXJ (29.5). Same filings, same arithmetic. Position in this list says nothing about which fund is better.